Zetia and Tadalafil Interaction: What Patients and Clinicians Need to Know

Does ezetimibe interact with tadalafil?

No pharmacokinetic or pharmacodynamic interaction between ezetimibe and tadalafil is described in either drug's FDA prescribing information, and the two drugs are cleared through separate metabolic pathways with no overlapping physiological effect. This is not the same as saying "no interaction exists between everything either drug touches." Both ezetimibe and tadalafil have other, genuinely important interactions, and confusing "ezetimibe's interactions" with "tadalafil's interactions" is a real source of patient and pharmacist confusion when the two are filled on the same day.

Ezetimibe (brand name Zetia) is FDA-approved to lower LDL cholesterol, either alone or added to a statin, by blocking intestinal cholesterol absorption. Tadalafil is FDA-approved under two brand names for two indications: Cialis, for erectile dysfunction and for benign prostatic hyperplasia symptoms, and Adcirca, a higher daily dose used for pulmonary arterial hypertension. Both drugs are commonly prescribed to the same population, men with cardiovascular risk factors, which is why the question comes up often even though the mechanisms do not overlap.

Why the metabolic pathways do not overlap

Ezetimibe is absorbed in the small intestine and undergoes extensive glucuronidation by UDP-glucuronosyltransferases (mainly UGT1A1 and UGT1A3) in the gut wall and liver. It is not meaningfully metabolized by cytochrome P450 enzymes. This pathway is described in ezetimibe's FDA prescribing information.

Tadalafil, by contrast, is predominantly cleared by CYP3A4. Tadalafil's FDA prescribing information identifies strong CYP3A4 inhibitors (for example, ketoconazole and ritonavir) as agents that raise tadalafil exposure enough to require dose reduction, and strong CYP3A4 inducers (for example, rifampin) as agents that can substantially lower tadalafil exposure. Because ezetimibe does not inhibit, induce, or depend on CYP3A4, it has no mechanism for altering tadalafil levels, and because tadalafil is not a meaningful modulator of UGT1A1 or UGT1A3, it has no mechanism for altering ezetimibe levels.

Why the pharmacodynamics do not overlap

Ezetimibe works at the brush border of the small intestine, blocking the NPC1L1 transporter that dietary and biliary cholesterol use to enter enterocytes. It has no vasodilatory activity and does not act on nitric oxide or cyclic GMP signaling.

Tadalafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in vascular smooth muscle. Higher cGMP relaxes smooth muscle, which produces the erectile response in the corpus cavernosum and reduces pulmonary vascular resistance at the higher Adcirca dose. Tadalafil also produces a small systemic blood pressure reduction on its own, and a much larger, dangerous one when combined with nitrates, because nitrates independently raise cGMP through a different enzyme (guanylate cyclase). Ezetimibe does not participate in this signaling pathway at any point, so it does not add to tadalafil's blood-pressure-lowering effect and does not create or worsen the nitrate interaction.

Ezetimibe (a cholesterol absorption inhibitor cleared by intestinal and hepatic glucuronidation) and tadalafil (a CYP3A4-cleared PDE5 inhibitor) do not share a metabolic enzyme, a transporter of clinical consequence, or a physiological target, and neither drug's FDA label lists the other as an interaction. The clinically meaningful interactions for this drug pair lie elsewhere: cyclosporine, fibrates, and bile acid sequestrants for ezetimibe, and nitrates, alpha-blockers, and strong CYP3A4 modulators for tadalafil.

What each drug's label actually flags

Ezetimibe's labeled interactions

According to the ezetimibe FDA label, the interactions with established clinical significance are:

• Cyclosporine, co-administration increases ezetimibe exposure; the combination is used with caution and LDL-C and cyclosporine level monitoring.
• Fibrates (gemfibrozil, fenofibrate), fibrates raise ezetimibe glucuronide concentrations; the combination is not contraindicated but warrants clinical judgment given both drugs affect lipid metabolism.
• Bile acid sequestrants (cholestyramine, colesevelam), sequestrants reduce ezetimibe absorption; the standard workaround is to take ezetimibe at least 2 hours before or 4 hours after the sequestrant.

Tadalafil does not appear in this list.

Tadalafil's labeled interactions

According to the tadalafil FDA label, the interactions with established clinical significance are:

• Nitrates, in any form, the label describes this combination as contraindicated because of the risk of severe, potentially fatal hypotension when PDE5 inhibition and nitrate-driven vasodilation are combined. This applies to scheduled nitrates and to as-needed sublingual nitroglycerin.
• Alpha-blockers (tamsulosin, doxazosin, terazosin, and others), additive blood pressure lowering; the label describes a titration approach when both drug classes are used.
• Strong CYP3A4 inhibitors (for example, ritonavir, ketoconazole), these raise tadalafil exposure and require a lower, less frequent tadalafil dose.
• Strong CYP3A4 inducers (for example, rifampin), these can lower tadalafil exposure enough to reduce effectiveness.
• Other antihypertensives, modest additive blood pressure reduction that generally warrants counseling rather than a dose change.

Ezetimibe does not appear in this list.

The interaction that actually matters: nitrates, not ezetimibe

Because ezetimibe and tadalafil are both common in cardiovascular patients, there is a real risk of conflating "ezetimibe's interactions" with "tadalafil's interactions." A patient on ezetimibe for dyslipidemia who also uses a nitrate for angina, and who is then prescribed tadalafil for erectile dysfunction, has a genuine contraindication driven by the tadalafil-nitrate combination. Ezetimibe is not part of that risk. Anyone prescribing or dispensing tadalafil should confirm the patient is not using any nitrate, including as-needed sublingual nitroglycerin that a patient may not think to mention unless directly asked.

What the trial evidence supports, and what it does not

Ezetimibe's outcome evidence comes from large statin-background trials, most notably a cardiovascular outcomes trial in patients after acute coronary syndrome and a chronic kidney disease trial, both of which tested ezetimibe added to a statin against a statin alone. These trials were not designed to evaluate PDE5 inhibitor co-use and did not report a cardiovascular safety signal tied to erectile dysfunction medication. Separately, PDE5 inhibitors including tadalafil have been studied in men with cardiovascular disease, generally without an increase in major cardiovascular events when nitrates are excluded from the population studied. Readers who want the exact effect sizes from these trials should consult the original publications directly rather than relying on secondary figures, since precise numbers from this class of trial vary by population, follow-up length, and endpoint definition.

Evidence boundary: what is established, plausible, and unproven

Established, based on the current FDA labels for both drugs: ezetimibe is cleared by glucuronidation and is not a meaningful CYP3A4 substrate, inhibitor, or inducer; tadalafil is cleared by CYP3A4; neither label lists the other drug as an interaction; tadalafil is contraindicated with nitrates; tadalafil requires dose adjustment with alpha-blockers, strong CYP3A4 inhibitors, strong CYP3A4 inducers, and reduced renal function.

Plausible but not separately tested, based on mechanism: because the two drugs use non-overlapping enzymes and targets, long-term co-administration is mechanistically unlikely to produce a delayed or cumulative interaction. This has not been studied as a dedicated combination and rests on pathway reasoning rather than a trial designed to test the pair together.

Not established: there is no dedicated pharmacokinetic interaction study of ezetimibe co-administered with tadalafil in the published literature reviewed for this article. The absence of an interaction on either label reflects the absence of a plausible mechanism and postmarketing signal, not the existence of a formal crossover study. Clinicians relying on this article for an unusual clinical scenario (for example, severe hepatic or renal impairment in combination with polypharmacy) should verify against the current label text and a pharmacist-reviewed interaction database, since label language is updated periodically and this summary reflects the label versions cited above.

Evidence-status interaction assessment: ezetimibe plus tadalafil

Counseling checklist for co-prescribed patients

1. Confirm no nitrate use before tadalafil is started or refilled: sublingual nitroglycerin, isosorbide mononitrate or dinitrate, nitroglycerin patches or paste, and recreational nitrite use all count. Ezetimibe is not part of this screen.
2. Confirm alpha-blocker status. If the patient takes tamsulosin, doxazosin, or terazosin, tadalafil initiation follows the labeled titration approach. Ezetimibe has no interaction with alpha-blockers.
3. No timing separation is needed between ezetimibe and tadalafil. The 2-hour-before or 4-hour-after rule applies to ezetimibe taken with a bile acid sequestrant, not to tadalafil.
4. Ask about new chest pain. A patient on tadalafil who develops chest pain should not take nitroglycerin without telling the prescriber, because of the hypotension risk described above. This holds regardless of ezetimibe use.
5. Keep lipid monitoring on its usual schedule. Ezetimibe's cholesterol-lowering effect is checked with a fasting lipid panel some weeks after starting or changing dose, per standard lipid-management practice; this schedule is unrelated to tadalafil use.

When to seek urgent care

Chest pain, fainting, or a sudden, marked drop in blood pressure after taking tadalafil, especially in anyone who has also taken a nitrate in any form, is a medical emergency and warrants immediate evaluation. This risk comes from the tadalafil-nitrate interaction, not from ezetimibe. Ezetimibe itself is not associated with an acute cardiovascular emergency; its main monitoring concern is liver enzymes in the context of combination therapy with a statin, which should be discussed with the prescribing clinician rather than managed by self-adjustment.